Partnership to advance therapy for diabetes
A story about Sanofi and Provention Bio's alliance on the first ever disease-modifying therapy for type 1 diabetes (T1D) patients got people sharing on social media networks.
The US Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for TZIELD (teplizumab-mzwv) in November. It is an anti-CD3-directed antibody, for intravenous use, and the first and only immunomodulatory treatment to delay the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older with stage 2 T1D.
Photo credit: GettyImages/Guido Mieth
